Agios – Mitapivat sNDA in Sickle Cell Disease

Summary Agios Pharmaceuticals submitted a supplemental NDA to the FDA seeking accelerated approval of mitapivat for sickle cell disease, positioning the oral PKR activator in a highly competitive emerging therapeutic class. What Happened Agios submitted its sNDA for mitapivat in adults and adolescents with sickle…